Statement Regarding Unaudited Financial Information
The unaudited financial information set forth above is subject to adjustments that may be identified when audit work is performed on our year- end financial statements, which could result in significant differences from this unaudited financial information.
Currency Convenience Translation
For the convenience of readers, certain RMB amounts have been translated into US dollars at the rate of RMB6.8591 to US$1.00, the noon buying rate for US dollars in effect on June 30, 2008 for cable transfers of RMB per US dollar as certified for customs purposes by the Federal Reserve Bank of New York.
AMAG Partnership - In May 2008, we announced the signing of a strategic
partnership with Boston-based AMAG Pharmaceuticals, Inc. to develop and
commercialize ferumoxytol, a new generation intravenous iron replacement
therapeutic agent to treat iron deficiency anemia in chronic kidney disease
("CKD") patients and potential other indications outside the nephrology
segment. We believe this partnership demonstrates our ability to formulate
and execute our business development strategy, and represents a validation
of our commercial infrastructure and leading position in the nephrology
therapeutic market in China. This partnership is a significant step towards
achieving our goal of becoming the partner of choice in China for
biotechnology companies worldwide, and, as a result, is expected to enhance
the long term growth prospects of the c
|SOURCE 3SBio Inc.|
Copyright©2008 PR Newswire.
All rights reserved